{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:15:59Z","timestamp":1790615759126,"version":"4.1.0"},"reference-count":193,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jaccao.2022.11.006","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T14:06:16Z","timestamp":1671545176000},"page":"563-578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cancer Immunotherapy Beyond Checkpoint Blockade"],"prefix":"10.1016","volume":"4","author":[{"given":"Nathan E.","family":"Welty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saar I.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccao.2022.11.006_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jaccao.2022.11.006_bib2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O\u2019Donnell","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib3","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.jaccao.2022.11.006_bib4","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrm2858","article-title":"Genomic instability\u2014an evolving hallmark of cancer","volume":"11","author":"Negrini","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax7918","article-title":"Neoantigen quality, not quantity","volume":"11","author":"McGranahan","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib6","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib7","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.it.2018.04.005","article-title":"Update on tumor neoantigens and their utility: why it is good to be different","volume":"39","author":"Lee","year":"2018","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jaccao.2022.11.006_bib9","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jaccao.2022.11.006_bib10","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","article-title":"Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction","volume":"183","author":"Wells","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jaccao.2022.11.006_bib11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-genom-091212-153455","article-title":"Major histocompatibility complex genomics and human disease","volume":"14","author":"Trowsdale","year":"2013","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.jaccao.2022.11.006_bib13","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.humimm.2007.04.005","article-title":"High-resolution HLA alleles and haplotypes in the United States population","volume":"68","author":"Maiers","year":"2007","journal-title":"Hum Immunol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib14","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1126\/science.aaa3828","article-title":"Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells","volume":"348","author":"Carreno","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jaccao.2022.11.006_bib15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jaccao.2022.11.006_bib16","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jaccao.2022.11.006_bib17","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jaccao.2022.11.006_bib18","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1038\/s41467-021-24562-2","article-title":"Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting","volume":"12","author":"Bear","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaccao.2022.11.006_bib19","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.cllc.2014.06.002","article-title":"Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation","volume":"15","author":"Chaft","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jaccao.2022.11.006_bib20","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","article-title":"Identifying and targeting human tumor antigens for t cell-based immunotherapy of solid tumors","volume":"38","author":"Leko","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jaccao.2022.11.006_bib21","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-cell transfer therapy targeting mutant KRAS in cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib22","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jaccao.2022.11.006_bib23","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1158\/0008-5472.CAN-20-1072","article-title":"A\u00a0genetic vaccine encoding shared cancer neoantigens to treat tumors with microsatellite instability","volume":"80","author":"Leoni","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaccao.2022.11.006_bib24","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib25","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.urology.2013.01.061","article-title":"Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial","volume":"81","author":"Schellhammer","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.jaccao.2022.11.006_bib26","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S1470-2045(16)00099-1","article-title":"Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Vansteenkiste","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1470-2045(13)70510-2","article-title":"Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial","volume":"15","author":"Butts","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib28","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S1470-2045(14)70236-0","article-title":"Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial","volume":"15","author":"Middleton","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib29","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib30","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/nm.3161","article-title":"Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells","volume":"19","author":"Robbins","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib31","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/annonc\/mdz398","article-title":"Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis","volume":"30","author":"Dafni","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib32","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1158\/1078-0432.CCR-17-3649","article-title":"Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome","volume":"24","author":"Forget","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaccao.2022.11.006_bib33","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib34","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","article-title":"Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial","volume":"27","author":"Creelan","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib35","doi-asserted-by":"crossref","first-page":"41339","DOI":"10.18632\/oncotarget.5463","article-title":"A\u00a0phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma","volume":"6","author":"Jiang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaccao.2022.11.006_bib36","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1158\/1078-0432.CCR-18-2722","article-title":"A\u00a0phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers","volume":"25","author":"Stevanovic","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaccao.2022.11.006_bib37","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1470-2045(17)30251-6","article-title":"Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study","volume":"18","author":"Chandran","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib38","first-page":"86","article-title":"Cardiovascular toxicity and mortality associated with adoptive cell therapy and tumor-infiltrating lymphocytes for advanced stage melanoma","volume":"44","author":"Fradley","year":"2021","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.jaccao.2022.11.006_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/science.aad1067","article-title":"Programming gene and engineered-cell therapies with synthetic biology","volume":"359","author":"Kitada","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jaccao.2022.11.006_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jaccao.2022.11.006_bib41","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41591-022-01765-8","article-title":"Engineered cellular immunotherapies in cancer and beyond","volume":"28","author":"Finck","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib42","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cell.2020.03.001","article-title":"The emerging landscape of immune cell therapies","volume":"181","author":"Weber","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jaccao.2022.11.006_bib43","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1158\/2326-6066.CIR-15-0188","article-title":"Identification of T-cell receptors targeting KRAS-mutated human tumors","volume":"4","author":"Wang","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jaccao.2022.11.006_bib44","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","article-title":"Neoantigen T-cell receptor gene therapy in pancreatic cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib45","doi-asserted-by":"crossref","first-page":"19322","DOI":"10.1074\/jbc.RA119.010251","article-title":"An engineered antibody fragment targeting mutant beta-catenin via major histocompatibility complex I neoantigen presentation","volume":"294","author":"Miller","year":"2019","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jaccao.2022.11.006_bib46","doi-asserted-by":"crossref","first-page":"9967","DOI":"10.1073\/pnas.1511996112","article-title":"Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes","volume":"112","author":"Skora","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaccao.2022.11.006_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abd5515","article-title":"Bispecific antibodies targeting mutant RAS neoantigens","volume":"6","author":"Douglass","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib48","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.11.006_bib49","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006034","article-title":"Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells","volume":"5","author":"Cameron","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib50","article-title":"Time to evolve: predicting engineered T cell-associated toxicity with next-generation models","volume":"10","author":"Donnadieu","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jaccao.2022.11.006_bib51","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in\u00a0vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib52","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1158\/0008-5472.CAN-21-1109","article-title":"Mechanisms of therapeutic antitumor monoclonal antibodies","volume":"81","author":"Tsao","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaccao.2022.11.006_bib53","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jamaoncol.2020.7932","article-title":"Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial","volume":"7","author":"Rugo","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib54","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-Cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib55","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1182\/bloodadvances.2020001942","article-title":"A\u00a0phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy","volume":"4","author":"Maloney","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaccao.2022.11.006_bib56","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.11.006_bib57","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib58","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1200\/JCO.1996.14.3.737","article-title":"Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2\/neu-overexpressing metastatic breast cancer","volume":"14","author":"Baselga","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib59","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1200\/JCO.1998.16.8.2659","article-title":"Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2\/neu monoclonal antibody plus cisplatin in patients with HER2\/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment","volume":"16","author":"Pegram","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib60","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib61","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jaccao.2022.11.006_bib62","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/0008-5472.CAN-13-1545","article-title":"Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer","volume":"74","author":"Alizadeh","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaccao.2022.11.006_bib63","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","article-title":"Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade","volume":"39","author":"Srivastava","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jaccao.2022.11.006_bib64","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaccao.2022.11.006_bib65","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib66","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study","volume":"39","author":"Park","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib67","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/cpt.1396","article-title":"Bispecific antibodies in the treatment of hematologic malignancies","volume":"106","author":"Duell","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaccao.2022.11.006_bib68","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib69","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1111\/ajd.13866","article-title":"A\u00a0review of the cutaneous toxicities of tebentafusp-Featuring two cases involving superficial bullous reactions","volume":"63","author":"Pham","year":"2022","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib70","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Gokbuget","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.11.006_bib71","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib72","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2015-06-649111","article-title":"Long-term survival and T-cell kinetics in relapsed\/refractory ALL patients who achieved MRD response after blinatumomab treatment","volume":"126","author":"Zugmaier","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.11.006_bib73","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.2003.09.027","article-title":"Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network","volume":"21","author":"Hainsworth","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib74","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2019-123742","article-title":"Mosunetuzumab induces complete remissions in poor prognosis non-hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines","volume":"134","author":"Schuster","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.11.006_bib75","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib76","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/ajh.24987","article-title":"Outcome of patients with relapsed\/refractory acute lymphoblastic leukemia after blinatumomab failure: no change in the level of CD19 expression","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib77","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz3339","article-title":"The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma","volume":"12","author":"Lulla","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib78","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.20.02224","article-title":"T-cell therapy for lymphoma using nonengineered multiantigen-targeted T cells is safe and produces durable clinical effects","volume":"39","author":"Vasileiou","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib79","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib80","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib81","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3389\/fonc.2020.00685","article-title":"Successful anti-CLL1 CAR T-cell therapy in secondary acute myeloid leukemia","volume":"10","author":"Zhang","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib82","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib83","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGFbeta-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib84","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jaccao.2022.11.006_bib85","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib86","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","article-title":"Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis","volume":"26","author":"Heczey","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib87","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41587-019-0329-2","article-title":"The therapeutic landscape for cells engineered with chimeric antigen receptors","volume":"38","author":"MacKay","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib88","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jaccao.2022.11.006_bib89","first-page":"613","article-title":"CAR T-cells: costs, comparisons, and commentary","volume":"22","author":"Hay","year":"2019","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.jaccao.2022.11.006_bib90","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib91","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaccao.2022.11.006_bib92","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib93","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib94","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib95","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaccao.2022.11.006_bib96","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib97","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nrclinonc.2018.19","article-title":"Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit \u201cALL\u201d","volume":"15","author":"Teachey","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib98","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib99","first-page":"193","article-title":"Cardiovascular effects of CAR T cell therapy: a retrospective study","volume":"2","author":"Lefebvre","year":"2020","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2022.11.006_bib100","article-title":"Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies","volume":"8","author":"Shalabi","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jaccao.2022.11.006_bib101","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.048100","article-title":"Chimeric antigen receptor T-cell therapy-associated cardiomyopathy in patients with refractory or relapsed non-Hodgkin lymphoma","volume":"142","author":"Ganatra","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2022.11.006_bib102","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jaccao.2022.11.006_bib103","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1080\/10428194.2019.1697814","article-title":"Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)","volume":"61","author":"Nahas","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaccao.2022.11.006_bib104","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaccao.2022.11.006_bib105","article-title":"New-onset severe cytopenia after CAR-T cell therapy: analysis of 76 patients with relapsed or refractory acute lymphoblastic leukemia","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib106","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1182\/blood-2009-10-248997","article-title":"Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens","volume":"115","author":"Warren","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.11.006_bib107","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1182\/blood-2008-03-077974","article-title":"Graft-versus-leukemia effects of transplantation and donor lymphocytes","volume":"112","author":"Kolb","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.11.006_bib108","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1182\/asheducation-2015.1.225","article-title":"Graft-versus-host disease versus graft-versus-leukemia","volume":"2015","author":"Negrin","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jaccao.2022.11.006_bib109","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200006223422501","article-title":"Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources","volume":"342","author":"Rocha","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib110","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1182\/blood-2007-03-081596","article-title":"Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia","volume":"110","author":"Schrezenmeier","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.11.006_bib111","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/sj.bmt.1704487","article-title":"Predictors for severe cardiac complications after hematopoietic stem cell transplantation","volume":"33","author":"Sakata-Yanagimoto","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaccao.2022.11.006_bib112","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1182\/bloodadvances.2018019117","article-title":"Prediction of cardiovascular disease among hematopoietic cell transplantation survivors","volume":"2","author":"Armenian","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaccao.2022.11.006_bib113","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/bmt.2016.331","article-title":"Pericardial effusion requiring surgical intervention after stem cell transplantation: a case series","volume":"52","author":"Pfeiffer","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaccao.2022.11.006_bib114","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-155-1-201107050-00004","article-title":"Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation","volume":"155","author":"Chow","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib115","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/bmt.2015.127","article-title":"Arrhythmias in the setting of hematopoietic cell transplants","volume":"50","author":"Tonorezos","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaccao.2022.11.006_bib116","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1016\/j.bbmt.2019.07.027","article-title":"Severe cytokine release syndrome after haploidentical peripheral blood stem cell transplantation","volume":"25","author":"Imus","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaccao.2022.11.006_bib117","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s11239-020-02344-9","article-title":"Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation","volume":"51","author":"Rotz","year":"2021","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.jaccao.2022.11.006_bib118","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11912-019-0774-6","article-title":"Cardiac complications in the adult bone marrow transplant patient","volume":"21","author":"Tuzovic","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jaccao.2022.11.006_bib119","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jaccao.2022.11.006_bib120","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib121","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jaccao.2022.11.006_bib122","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8\u00a0T cell exhaustion during chronic viral infection and cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib123","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41590-019-0512-0","article-title":"Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups","volume":"20","author":"Andrews","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib124","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib125","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib126","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib127","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib128","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1200\/JCO.19.01464","article-title":"Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade","volume":"38","author":"Betof Warner","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib129","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaccao.2022.11.006_bib130","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib131","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaccao.2022.11.006_bib132","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.4_suppl.378","article-title":"A\u00a0phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1","volume":"40","author":"Oh","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib133","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib134","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib135","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib136","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib137","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib138","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.semcancer.2017.12.002","article-title":"Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics","volume":"52","author":"Hegde","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib139","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3389\/fimmu.2020.01956","article-title":"Anti-angiogenic agents in combination with immune checkpoint inhibitors: a promising strategy for cancer treatment","volume":"11","author":"Song","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib140","doi-asserted-by":"crossref","first-page":"S376","DOI":"10.1016\/j.annonc.2022.04.453","article-title":"Botensilimab, a novel innate\/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer","volume":"33","author":"Bullock","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib141","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1200\/JCO.22.00369","article-title":"Major adverse cardiac events with immune checkpoint inhibitors: a pooled analysis of trials sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program","volume":"40","author":"Naqash","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib142","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib143","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jaccao.2022.11.006_bib144","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib145","first-page":"182","article-title":"Immune checkpoint inhibitor-related adverse cardiovascular events in patients with lung cancer","volume":"1","author":"Chitturi","year":"2019","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2022.11.006_bib146","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.110.992230","article-title":"Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension","volume":"124","author":"Nazer","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2022.11.006_bib147","first-page":"24","article-title":"Increase in blood pressure associated with tyrosine kinase inhibitors targeting vascular endothelial growth factor","volume":"1","author":"Waliany","year":"2019","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2022.11.006_bib148","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib149","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1200\/JCO.21.01808","article-title":"Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors","volume":"40","author":"Laenens","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib150","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib151","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib152","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/cncr.23552","article-title":"High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006","volume":"113","author":"Klapper","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jaccao.2022.11.006_bib153","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1200\/JCO.2022.40.16_suppl.2500","article-title":"Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1","volume":"40","author":"Vaishampayan","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib154","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-10940-8","article-title":"Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment","volume":"7","author":"Yeku","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaccao.2022.11.006_bib155","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41586-021-03861-0","article-title":"An engineered IL-2 partial agonist promotes CD8+ T cell stemness","volume":"597","author":"Mo","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jaccao.2022.11.006_bib156","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg6986","article-title":"A\u00a0human orthogonal IL-2 and IL-2Rbeta system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib157","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8\u00a0T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib158","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib159","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3389\/fimmu.2020.01680","article-title":"The new era of cancer immunotherapy: targeting myeloid-derived suppressor cells to overcome immune evasion","volume":"11","author":"De Cicco","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib160","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1158\/0008-5472.CAN-14-0657","article-title":"Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes","volume":"74","author":"Kanterman","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaccao.2022.11.006_bib161","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","article-title":"5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity","volume":"70","author":"Vincent","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaccao.2022.11.006_bib162","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaccao.2022.11.006_bib163","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2147\/DDDT.S253232","article-title":"Pexidartinib, a novel small molecule CSF-1R inhibitor in use for tenosynovial giant cell tumor: a systematic review of pre-clinical and clinical development","volume":"14","author":"Benner","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jaccao.2022.11.006_bib164","doi-asserted-by":"crossref","first-page":"86522","DOI":"10.18632\/oncotarget.13287","article-title":"Increasing the efficacy of radiotherapy by modulating the CCR2\/CCR5 chemokine axes","volume":"7","author":"Connolly","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaccao.2022.11.006_bib165","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.ymthe.2022.02.005","article-title":"Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33\/CD3\u00a0T cell engager, ex\u00a0vivo in MDS and melanoma","volume":"30","author":"Cheng","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaccao.2022.11.006_bib166","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1158\/2159-8290.CD-16-0850","article-title":"Overcoming the immunosuppressive tumor microenvironment of hodgkin lymphoma using chimeric antigen receptor T cells","volume":"7","author":"Ruella","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jaccao.2022.11.006_bib167","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-126271","article-title":"The first-in-class anti-CD47 antibody magrolimab (5F9) in combination with azacitidine is effective in MDS and AML patients: ongoing phase 1b results","volume":"134","author":"Sallman","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.11.006_bib168","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1470-2045(20)30532-5","article-title":"CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study","volume":"22","author":"O\u2019Hara","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib169","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padron","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib170","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(67)92837-1","article-title":"Immunological aspects of malignant disease","volume":"1","author":"Burnet","year":"1967","journal-title":"Lancet"},{"key":"10.1016\/j.jaccao.2022.11.006_bib171","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ccell.2020.07.004","article-title":"Clinical challenges of immune checkpoint inhibitors","volume":"38","author":"de Miguel","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jaccao.2022.11.006_bib172","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41571-018-0111-2","article-title":"Hyperprogressive disease: recognizing a novel pattern to improve patient management","volume":"15","author":"Champiat","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib173","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ccell.2018.03.008","article-title":"The immune revolution: a case for priming, not checkpoint","volume":"33","author":"Vonderheide","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jaccao.2022.11.006_bib174","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/hon.2828","article-title":"Obinutuzumab-related adverse events: a systematic review and meta-analysis","volume":"39","author":"Amitai","year":"2021","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib175","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib176","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib177","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib178","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib179","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib180","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaccao.2022.11.006_bib181","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib182","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaccao.2022.11.006_bib183","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.11.006_bib184","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaccao.2022.11.006_bib185","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nri2970","article-title":"Harnessing the biology of IL-7 for therapeutic application","volume":"11","author":"Mackall","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib186","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1038\/s41467-022-30860-0","article-title":"A\u00a0long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity","volume":"13","author":"Kim","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaccao.2022.11.006_bib187","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/cts.12800","article-title":"hIL-7-hyFc, A long-acting IL-7, increased absolute lymphocyte count in healthy subjects","volume":"13","author":"Lee","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jaccao.2022.11.006_bib188","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2016.68.1106","article-title":"Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors","volume":"34","author":"Naing","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.11.006_bib189","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1158\/1078-0432.CCR-18-1512","article-title":"First-in-human phase I trial of a tumor-targeted cytokine (NHS-IL12) in subjects with metastatic solid tumors","volume":"25","author":"Strauss","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaccao.2022.11.006_bib190","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1182\/bloodadvances.2018028332","article-title":"First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia","volume":"3","author":"Cooley","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaccao.2022.11.006_bib191","first-page":"151","article-title":"A\u00a0dose-escalation study of recombinant human interleukin-18 in combination with ofatumumab after autologous peripheral blood stem cell transplantation for lymphoma","volume":"41","author":"Robertson","year":"2018","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.jaccao.2022.11.006_bib192","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1517\/14712598.2010.480971","article-title":"Interleukin-21: updated review of phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed\/refractory indolent non-Hodgkin\u2019s lymphoma","volume":"10","author":"Hashmi","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jaccao.2022.11.006_bib193","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1200\/JCO.2007.14.5193","article-title":"Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma","volume":"26","author":"Thompson","year":"2008","journal-title":"J\u00a0Clin Oncol"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087322004616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087322004616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T19:08:09Z","timestamp":1727377689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087322004616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":193,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2666087322004616"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2022.11.006","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer Immunotherapy Beyond Checkpoint Blockade","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2022.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}